GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Current Ratio

Biotech Acquisition Co (Biotech Acquisition Co) Current Ratio : 0.03 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Biotech Acquisition Co's current ratio for the quarter that ended in Sep. 2022 was 0.03.

Biotech Acquisition Co has a current ratio of 0.03. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Biotech Acquisition Co has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Biotech Acquisition Co's Current Ratio or its related term are showing as below:

BIOT's Current Ratio is not ranked *
in the Diversified Financial Services industry.
Industry Median: 1.12
* Ranked among companies with meaningful Current Ratio only.

Biotech Acquisition Co Current Ratio Historical Data

The historical data trend for Biotech Acquisition Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Current Ratio Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
Current Ratio
- 0.95

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Current Ratio Get a 7-Day Free Trial Premium Member Only 1.88 0.95 0.14 0.04 0.03

Competitive Comparison of Biotech Acquisition Co's Current Ratio

For the Shell Companies subindustry, Biotech Acquisition Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotech Acquisition Co's Current Ratio Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's Current Ratio falls into.



Biotech Acquisition Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Biotech Acquisition Co's Current Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=0.299/0.314
=0.95

Biotech Acquisition Co's Current Ratio for the quarter that ended in Sep. 2022 is calculated as

Current Ratio (Q: Sep. 2022 )=Total Current Assets (Q: Sep. 2022 )/Total Current Liabilities (Q: Sep. 2022 )
=0.095/3.518
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotech Acquisition Co  (NAS:BIOT) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Biotech Acquisition Co Current Ratio Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By GlobeNewswire GlobeNewswire 02-02-2023